A sea change has occurred in the treatment options available for metastatic urothelial
bladder cancer with the recent Food and Drug Administration approval of 5 immune …

The treatment landscape of urothelial cancers has evolved in the last decade with the
approval of chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody …

The Third Annual Albert Institute Bladder Symposium was held on September 8–10th, 2016,
in Denver Colorado. Participants discussed several critical topics in the field of bladder …

Bladder cancer is a heterogeneous disease. Interpatient heterogeneity in response to a drug
limits treatment options and impairs improvement of patient survival. For example …

Purpose Urothelial carcinoma of the bladder (UCB) is a common malignancy with limited
systemic treatment options in advanced stages. Despite recent advances in immunotherapy …

Urothelial malignancies, including carcinomas of the bladder, ureters, and renal pelvis
comprised∼ 8% of new cancer cases in the USA in 2016. In the metastatic setting, 15% of …

For the management of bladder cancer, 2018 has been characterized by deepened
knowledge on the molecular basis of invasive bladder cancer and its potential interaction …

Deciphering the molecular pathways of bladder cancer has accelerated the identification of
prognostic and theranostic markers, allowed for the development of novel noninvasive early …

Effective management of advanced urothelial bladder cancer is challenging. New
discoveries that improve our understanding of molecular bladder cancer subtypes have …

Urothelial carcinoma of the bladder is a heterogeneous disease with many challenges for
clinicians and patients alike. However, for the most part of the last three decades, treatment …